2.21
-0.07(-3.07%)
Currency In USD
| Previous Close | 2.28 |
| Open | 2.31 |
| Day High | 2.32 |
| Day Low | 2.2 |
| 52-Week High | 3.2 |
| 52-Week Low | 1.26 |
| Volume | 68,621 |
| Average Volume | 261,711 |
| Market Cap | 63.72M |
| PE | -2.87 |
| EPS | -0.77 |
| Moving Average 50 Days | 2.51 |
| Moving Average 200 Days | 2.08 |
| Change | -0.07 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $602.18 as of August 22, 2025 at a share price of $2.21. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $1,078.05 as of August 22, 2025 at a share price of $2.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma Announces Other Serious Diseases Strategy
GlobeNewswire Inc.
Aug 06, 2025 4:30 PM GMT
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/r
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
GlobeNewswire Inc.
Jul 11, 2025 1:36 PM GMT
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
GlobeNewswire Inc.
Jul 07, 2025 1:35 PM GMT
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA,